MedPath

Botulinum toxin type A

Generic Name
Botulinum toxin type A
Brand Names
Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
Drug Type
Biotech
Chemical Formula
-
CAS Number
93384-43-1
Unique Ingredient Identifier
0A6JH35GMQ
Background

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions. A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.

Indication

Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.

In addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence, treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy. Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus, and disorders of the 7th cranial nerve.

Off-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain, neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.

Associated Conditions
Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis
Associated Therapies
-

Effectiveness of Botulinum Toxin A in Preventing Scar Formation and Initial Exploration of "Optimal Concentration"

Early Phase 1
Completed
Conditions
Scar
Interventions
First Posted Date
2024-05-31
Last Posted Date
2024-05-31
Lead Sponsor
Dezhou Hospital Qilu Hospital of Shandong University
Target Recruit Count
50
Registration Number
NCT06437912
Locations
🇨🇳

Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, Shandong, China

SURGERY VS BOTULINUM TOXIN ON QUALITY OF LIFE IN STROKE PATIENTS: RANDOMIZED TRIAL

Not Applicable
Recruiting
Conditions
Stroke
Interventions
Drug: Botulinum Toxin A
Procedure: spastic hand sugery
First Posted Date
2024-04-30
Last Posted Date
2024-04-30
Lead Sponsor
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Target Recruit Count
44
Registration Number
NCT06392633
Locations
🇪🇸

University of Granada, Granada, Spain

Assessing the Impact of Botulinum Toxin Type A on Facial Wrinkles: A Comprehensive Clinical Investigation

Recruiting
Conditions
Wrinkle
Interventions
First Posted Date
2024-04-25
Last Posted Date
2024-05-24
Lead Sponsor
Global Aesthetics LLC
Target Recruit Count
500
Registration Number
NCT06385171
Locations
🇺🇸

Global Aesthetics LLC, Lubbock, Texas, United States

Botulinum Toxin Injection in the UES for R-CPD

Phase 4
Not yet recruiting
Conditions
Retrograde Cricopharyngeus Dysfunction
Interventions
Drug: Sodium Chloride 0.9% Inj
Drug: botulinum toxin type A
First Posted Date
2024-04-10
Last Posted Date
2024-04-10
Lead Sponsor
AZ Delta
Target Recruit Count
30
Registration Number
NCT06356025

Effectiveness of Botulinum Toxin A in Preventing Scar Formation and Initial Exploration of "Optimal Concentration"

Early Phase 1
Active, not recruiting
Conditions
Scar
Interventions
First Posted Date
2024-04-05
Last Posted Date
2024-04-05
Lead Sponsor
Qilu Hospital of Shandong University
Target Recruit Count
50
Registration Number
NCT06349733
Locations
🇨🇳

Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, Shandong, China

Intradermal BoNT-A Treatment in Erythematotelangiectatic Rosacea

Phase 4
Completed
Conditions
Erythematotelangiectatic Rosacea
Interventions
First Posted Date
2024-03-26
Last Posted Date
2024-03-29
Lead Sponsor
Istanbul Training and Research Hospital
Target Recruit Count
30
Registration Number
NCT06331533
Locations
🇹🇷

Istanbul Training and Research Hospital, Istanbul, Turkey

Ultrasound-guided Botulinum Toxin Injection on Cricopharyngeal Muscle Dysfunction

Not Applicable
Not yet recruiting
Conditions
Cricopharyngeal Achalasia
Interventions
Drug: botulinum toxin type A
Procedure: Injection
First Posted Date
2024-03-25
Last Posted Date
2024-03-25
Lead Sponsor
Copka Sonpashan
Target Recruit Count
30
Registration Number
NCT06328556

Safety and Efficacy of Botulinum Toxin A in Patients With Trigeminal Neuralgia

Phase 3
Recruiting
Conditions
Trigeminal Neuralgia
Interventions
Other: Isotonic saline
Drug: Botulinum toxin A
First Posted Date
2024-03-18
Last Posted Date
2024-03-18
Lead Sponsor
Henrik Schytz
Target Recruit Count
80
Registration Number
NCT06315790
Locations
🇩🇰

Danish Headache Center, Glostrup, Denmark

Comparative Study of the Effects of Dry Needling and Botulinum Toxin Type A as a Treatment for Lower Limb Post-stroke Spasticity

Phase 2
Not yet recruiting
Conditions
Stroke
Interventions
Other: Dry Needling
Drug: Botulinum toxin type A
First Posted Date
2024-03-06
Last Posted Date
2024-06-24
Lead Sponsor
Universiteit Antwerpen
Target Recruit Count
90
Registration Number
NCT06296082
Locations
🇪🇸

Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain

🇨🇦

Jewish Rehabilitation Hospital, Montréal, Quebec, Canada

🇧🇪

Universiteit Antwerpen, Antwerpen, Flandes, Belgium

Botulinum Toxin-A for Hidradenitis Suppurativa

Phase 4
Not yet recruiting
Conditions
Hidradenitis Suppurativa
Hidradenitis Suppurativa, Acne Inversa
Hidradenitis Suppurativa \(HS\)
Interventions
Drug: Normal saline
Drug: Botulinum toxin type A
First Posted Date
2024-02-01
Last Posted Date
2024-12-06
Lead Sponsor
Yale University
Target Recruit Count
30
Registration Number
NCT06237465
Locations
🇺🇸

Yale Medicine Multispecialty Clinic, Guilford, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath